Insmed Incorporated (NASDAQ:INSM) CEO Sells $1,519,312.50 in Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of Insmed stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $27,079,091.58. This represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

William Lewis also recently made the following trade(s):

• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total value of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.94, for a total value of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The shares were sold at an average price of $70.18, for a total value of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total value of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The shares were sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Stock Down 3.0 %

Insmed stock opened at $81.06 on Friday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91. The firm has a market cap of $14.50 billion, a price-to-earnings ratio of -14.50 and a beta of 1.11. The stock has a fifty day simple moving average of $74.29 and a two-hundred day simple moving average of $73.59.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Equities analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Institutional Trading of Insmed

Several large investors have recently modified their holdings of the company. Mackenzie Financial Corp grew its holdings in shares of Insmed by 12.5% in the fourth quarter. Mackenzie Financial Corp now owns 10,883 shares of the biopharmaceutical company’s stock worth $751,000 after acquiring an additional 1,213 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Insmed in the fourth quarter worth $259,000. Fourth Dimension Wealth LLC bought a new stake in shares of Insmed in the fourth quarter worth $278,000. Vise Technologies Inc. grew its holdings in Insmed by 6.3% during the fourth quarter. Vise Technologies Inc. now owns 5,634 shares of the biopharmaceutical company’s stock valued at $389,000 after purchasing an additional 336 shares during the period. Finally, Castleark Management LLC grew its holdings in Insmed by 21.9% during the fourth quarter. Castleark Management LLC now owns 52,780 shares of the biopharmaceutical company’s stock valued at $3,644,000 after purchasing an additional 9,480 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on INSM. Morgan Stanley raised their target price on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. HC Wainwright reiterated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research note on Wednesday. JPMorgan Chase & Co. lifted their price objective on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. Finally, Stifel Nicolaus lowered their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $91.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.